Business
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
- Total Revenues Grew 17% in the Second Quarter 2021 Compared to Second Quarter 2020 - Raising Full-year 2021 Financial Guidance - Marketing Authorization
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"- Total Revenues Grew 17% in the Second Quarter 2021 Compared to Second Quarter 2020\n - Raising Full-year 2021 Financial Guidance\n - Marketing Authorization Application (MAA) for Valoctocogene Roxaparvovec, for the Treatment of Severe Hemophilia A, Validated by European Medicines Agency; CHMP Opinion Expected First Half 2022\n - Positive CHMP Opinion Received in Europe for VOXZOGO™ for the Treatment of Children with Achondroplasia from Age 2 until Growth Plates Close; European Commission Decision expected in the Third Quarter 2021\n - FDA Review of VOXZOGO Proceeding; PDUFA Target Action Date November 20, 2021\n - BioMarin to Showcase Development Pipeline at R&D Day November 2021\n\n\nSAN RAFAEL, Calif., July 28, 2021 /PRNewswire/ --\n\n \n \n \n \n \n \n\n \nFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)\nThree Months Ended June 30,\nSix Months Ended June 30,\n2021\n2020\n% Change\n2021\n2020\n% Change\nTotal Revenues\n$\n501.7\n$\n429.5\n17\n%\n$\n987.7\n$\n931.6\n6\n%\nNet Product Revenues Marketed by BioMarin (1)\n$\n458.6\n$\n386.8\n19\n%\n$\n876.3\n$\n820.1\n7\n%\nVimizim Net Product Revenues\n$\n171.7\n$\n116.7\n47\n%\n$\n329.9\n$\n253.9\n30\n%\nNaglazyme Net Product Revenues\n$\n118.8\n$\n81.0\n47\n%\n$\n226.1\n$\n195.3\n16\n%\nKuvan Net Product Revenues\n$\n78.8\n$\n122.6\n(36)\n%\n$\n149.6\n$\n244.6\n(39)\n%\nPalynziq Net Product Revenues\n$\n59.0\n$\n40.7\n45\n%\n$\n113.0\n$\n75.3\n50\n%\nBrineura Net Product Revenues\n$\n30.3\n$\n25.8\n17\n%\n$\n57.7\n$\n49.8\n16\n%\nAldurazyme Net Product Revenues\n$\n28.1\n$\n32.3\n(13)\n%\n$\n78.1\n$\n88.0\n(11)\n%\nGAAP Net Income (Loss)\n$\n12.9\n$\n(29.2)\n$\n30.3\n$\n52.2\nGAAP Net Income (Loss) per Share – Basic\n$\n0.07\n$\n(0.16)\n$\n0.17\n$\n0.29\nGAAP Net Income (Loss) per Share – Diluted\n$\n0.07\n$\n(0.16)\n$\n0.16\n$\n0.28\nNon-GAAP Income (2)\n$\n97.8\n$\n57.4\n$\n202.1\n$\n173.9\n \nJune 30,2021\nDecember 31,2020\nCash, cash equivalents and investments\n$\n1,473.6\n$\n1,350.9\n(1)\nNet Product Revenues Marketed by BioMarin is the sum of revenues from Vimizim, Kuvan, Naglazyme, Palynziq, Brineura for the three and six months ended June 30, 2021 and includes Firdapse for the six months ended June 30, 2020, each calculated in accordance with Generally Accepted Accounting Principles in the United States (U.S. GAAP). Sanofi Genzyme ...